Abstract
The mechanism of multidrug resistance (MDR) reversal is not fully understood yet. Interaction of MDR modifiers with lipid bilayer of cell membranes and alterations of fluidity or other biophysical properties of plasma membrane might be an important factor in mechanism of MDR modulation and reversal. In this review we focus on phenothiazines which belong to the group of drugs known to modify MDR in different types of cells, from cancer cells up to various kinds of microorganisms. First, the aggregation properties of phenothiazines and their interactions with lipid bilayers are described. The localization of phenothazine derivative molecules in bilayers and alteration of membrane properties are discussed. Apart from the influence on model bilayers also the interactions of phenothiazines with cellular membranes (especially of erythrocytes) are reviewed. In subsequent sections the anti-MDR activity of phenothiazine derivatives observed in microorganisms and in cancer cells is described. The possible molecular mechanisms involved in MDR reversal by these compounds are presented. The direct interactions of phenothiazines with multidrug transporters and other effects of these modulators on plasma membranes are discussed. Finally, the structural features of phenothiazine derivatives essential for their optimal MDR reversal activity are described.
Keywords: Phenothiazines, multidrug resistance (MDR), P-glycoprotein, drug-membrane interactions, lipid bilayers, chlorpromazine, trifluoperazine, thioridazine
Current Drug Targets
Title: Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal
Volume: 7 Issue: 9
Author(s): K. Michalak, O. Wesolowska, N. Motohashi, J. Molnar and A. B. Hendrich
Affiliation:
Keywords: Phenothiazines, multidrug resistance (MDR), P-glycoprotein, drug-membrane interactions, lipid bilayers, chlorpromazine, trifluoperazine, thioridazine
Abstract: The mechanism of multidrug resistance (MDR) reversal is not fully understood yet. Interaction of MDR modifiers with lipid bilayer of cell membranes and alterations of fluidity or other biophysical properties of plasma membrane might be an important factor in mechanism of MDR modulation and reversal. In this review we focus on phenothiazines which belong to the group of drugs known to modify MDR in different types of cells, from cancer cells up to various kinds of microorganisms. First, the aggregation properties of phenothiazines and their interactions with lipid bilayers are described. The localization of phenothazine derivative molecules in bilayers and alteration of membrane properties are discussed. Apart from the influence on model bilayers also the interactions of phenothiazines with cellular membranes (especially of erythrocytes) are reviewed. In subsequent sections the anti-MDR activity of phenothiazine derivatives observed in microorganisms and in cancer cells is described. The possible molecular mechanisms involved in MDR reversal by these compounds are presented. The direct interactions of phenothiazines with multidrug transporters and other effects of these modulators on plasma membranes are discussed. Finally, the structural features of phenothiazine derivatives essential for their optimal MDR reversal activity are described.
Export Options
About this article
Cite this article as:
Michalak K., Wesolowska O., Motohashi N., Molnar J. and Hendrich B. A., Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal, Current Drug Targets 2006; 7 (9) . https://dx.doi.org/10.2174/138945006778226570
DOI https://dx.doi.org/10.2174/138945006778226570 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amyotrophic Lateral Sclerosis and Excitotoxicity: From Pathological Mechanism to Therapeutic Target
CNS & Neurological Disorders - Drug Targets Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review
Current Drug Therapy Epidemiology and Pathology of Malignant Mesothelioma
Current Respiratory Medicine Reviews A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Effects of Endocrine Disruptors on Developmental and Reproductive Functions
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Microtubule-targeting Anticancer Agents from Marine Natural Substance
Anti-Cancer Agents in Medicinal Chemistry Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents Role of Fractalkine (CX3CL1) in Regulating Neuron-Microglia Interactions: Development of Viral-Based CX3CR1 Antagonists
Current Alzheimer Research Cellular Targets and Mechanisms in the Cytotoxic Action of Non-biodegradable Engineered Nanoparticles
Current Drug Metabolism Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry